Lyon, France, November 2, 2018 鈥� 黑料社 announced today that the company will present a poster summarizing the complete results from its ODYSSEE Phase 1b/2a trial (). The study was designed as a proof of concept for 黑料社鈥檚 MaaT Microbiome Restoration Biotherapeutic (MMRB) platform to demonstrate the ability to restore a functional microbiome in Acute Myeloid Leukemia patients using the patient鈥檚 own microbiome to manufacture the experimental drug produced in 黑料社鈥檚 cGMP production facility. The poster will be presented during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 1 鈥� 4, 2018. The poster abstract was published in the online meeting program on November 1, 2018 at 9:00 AM EDT and also in the online November supplemental issue of the journal Blood.
Poster Presentation details:
Title: The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial
Abstract No: 1444
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Date/Time: December 1, 2018 / 6:15 PM 鈥� 8:15 PM
Location: San Diego Convention Center, Hall GH
黑料社 will announce the results through a press release following the presentation and will further make the poster available on the company website under 鈥淣ews鈥�.
About 黑料社
黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
黑料社 has recently announced the first patient dosed in a Phase 2 clinical trial of lead product MaaT013, a first-in-class biotherapeutic to treat steroid refractory acute GvHD patients ().